<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lauren B Elman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Leo McCluskey, MD, MBE</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive, presently incurable neurodegenerative disorder that causes muscle weakness, disability, and eventually death.</p><p>This topic will review the clinical evaluation and laboratory testing needed to support the diagnosis of ALS and other forms of motor neuron disease as well as the differential diagnosis of ALS. Other aspects of ALS are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease"</a> and  <a class="medical medical_review" href="/z/d/html/5156.html" rel="external">"Epidemiology and pathogenesis of amyotrophic lateral sclerosis"</a> and  <a class="medical medical_review" href="/z/d/html/5176.html" rel="external">"Familial amyotrophic lateral sclerosis"</a> and  <a class="medical medical_review" href="/z/d/html/5129.html" rel="external">"Symptom-based management of amyotrophic lateral sclerosis"</a> and  <a class="medical medical_review" href="/z/d/html/5128.html" rel="external">"Disease-modifying treatment of amyotrophic lateral sclerosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL EVALUATION</span><span class="headingEndMark"> — </span>ALS is one of multiple degenerative motor neuron diseases that are clinically defined based on the involvement of upper and/or lower motor neurons. ALS is the most common form of acquired motor neuron disease. Clinical manifestations of ALS include the presence of upper motor neuron and lower motor neuron signs, progression of disease, and the absence of an alternative explanation. There is no single diagnostic test that can confirm or entirely exclude the diagnosis of motor neuron disease.</p><p class="headingAnchor" id="H3"><span class="h2">History</span><span class="headingEndMark"> — </span>The diagnosis of ALS is suggested when there are progressive symptoms consistent with upper and lower motor neuron dysfunction that present in one of four body segments (cranial/bulbar, cervical, thoracic, and lumbosacral) followed by spread to other segments over a period of months to years. The course is not relapsing and remitting but rather is insidiously progressive. Involuntary weight loss and muscle wasting unrelated to nutrition may also occur.</p><p>The signs and symptoms associated with ALS are described in the tables for limb  (<a class="graphic graphic_table graphicRef72454" href="/z/d/graphic/72454.html" rel="external">table 1</a>), bulbar  (<a class="graphic graphic_table graphicRef75146" href="/z/d/graphic/75146.html" rel="external">table 2</a>), axial  (<a class="graphic graphic_table graphicRef67913" href="/z/d/graphic/67913.html" rel="external">table 3</a>), and respiratory  (<a class="graphic graphic_table graphicRef58537" href="/z/d/graphic/58537.html" rel="external">table 4</a>) locations.</p><p>In this setting, the diagnosis of ALS is further suggested by an absence of associated neuropathic or radiculopathic pain, sensory loss, sphincter dysfunction, ptosis, or extraocular muscle dysfunction. While sensory symptoms may occur in 20 to 30 percent of patients with ALS, the sensory examination is usually normal. (See  <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease", section on 'Sensory symptoms'</a>.)</p><p>Phenomena considered to exclude the diagnosis of ALS are ocular motility disturbances including supranuclear gaze paresis, tremor or other involuntary movements, cerebellar ataxia, extrapyramidal symptoms, and autonomic dysfunction. However, if one or more of these features occurs in the setting of otherwise typical ALS, this may be considered an ALS-plus syndrome. (See  <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease", section on 'ALS-plus syndrome'</a>.)</p><p>Cognitive dysfunction does not exclude the diagnosis of ALS. Frontotemporal behavioral or executive dysfunction can precede or follow the onset of motor symptoms in up to 40 percent of patients with ALS. In most cases, the symptoms are mild and possibly only detectable with formal cognitive testing. However, overt frontotemporal lobar dementia occurs in approximately 5 to 10 percent of patients with ALS and may be more common in patients with bulbar-onset ALS [<a href="#rid1">1-4</a>]. (See  <a class="medical medical_review" href="/z/d/html/5070.html" rel="external">"Frontotemporal dementia: Clinical features and diagnosis"</a>.)</p><p>Since approximately 10 percent of ALS cases are related to a genetic variant (ie, familial ALS), the history should include a thorough family history focused on any known diagnoses of ALS, other motor disorders, dementia, schizophrenia, and other neurodegenerative diseases. (See  <a class="medical medical_review" href="/z/d/html/5176.html" rel="external">"Familial amyotrophic lateral sclerosis"</a> and  <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease", section on 'ALS-plus syndrome'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The presence of both upper and lower motor neuron signs in multiple segments is required for the diagnosis of ALS. These are described in the tables for limb  (<a class="graphic graphic_table graphicRef72454" href="/z/d/graphic/72454.html" rel="external">table 1</a>), bulbar  (<a class="graphic graphic_table graphicRef75146" href="/z/d/graphic/75146.html" rel="external">table 2</a>), axial  (<a class="graphic graphic_table graphicRef67913" href="/z/d/graphic/67913.html" rel="external">table 3</a>), and respiratory  (<a class="graphic graphic_table graphicRef58537" href="/z/d/graphic/58537.html" rel="external">table 4</a>) signs and symptoms associated with ALS.</p><p>Lower motor neuron signs include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Weakness</p><p class="bulletIndent1"><span class="glyph">●</span>Fasciculations  (<a class="graphic graphic_movie graphicRef66062" href="/z/d/graphic/66062.html" rel="external">movie 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Muscular atrophy  (<a class="graphic graphic_movie graphicRef53274" href="/z/d/graphic/53274.html" rel="external">movie 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased muscle tone (flaccidity) and reduced or absent reflexes</p><p></p><p>Upper motor neuron signs include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased tone (spasticity) and increased extremity deep-tendon reflexes  (<a class="graphic graphic_movie graphicRef50755" href="/z/d/graphic/50755.html" rel="external">movie 3</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of any reflexes in muscles that are profoundly weak and wasted</p><p class="bulletIndent1"><span class="glyph">●</span>Pathologic reflexes such as crossed adductors, a jaw jerk, Hoffman sign, or Babinski sign [<a href="#rid5">5</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>The syndrome of pseudobulbar affect, which consists of inappropriate laughing, crying, and/or forced yawning</p><p></p><p>The Babinski sign (reflex great toe extension, often with fanning of the small toes, with lateral plantar stimulation) is present in approximately one-half of patients with ALS [<a href="#rid6">6</a>] but is a definitive indicator of upper motor neuron pathology when present  (<a class="graphic graphic_movie graphicRef74817" href="/z/d/graphic/74817.html" rel="external">movie 4</a>). In the absence of upper motor neuron pathology, lateral plantar stimulation produces reflex toe flexion without other leg or foot movement. Triple flexion, which is a manifestation of upper motor neuron disease, occurs when plantar stimulation produces reflex great toe extension, flexion of the knee, and flexion of the hip; in some cases, only the contraction of the tensor fasciae latae may be seen because of total loss of distal motor function [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H5"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of ALS is considered in patients with gradually progressive weakness occurring without associated pain or sensory impairment. The diagnosis of ALS is made in patients who meet diagnostic criteria assessed by history and physical examination, supported by electrodiagnostic studies, and not excluded by neuroimaging and laboratory studies. (See <a class="local">'Diagnostic criteria'</a> below and <a class="local">'Diagnostic evaluation'</a> below.)</p><p class="headingAnchor" id="H3738042690"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The criteria used for the diagnosis of ALS have evolved over time [<a href="#rid7">7</a>]. For many years, the clinical standard was the revised El Escorial World Federation of Neurology criteria, also known as the Airlie House criteria  (<a class="graphic graphic_algorithm graphicRef62831" href="/z/d/graphic/62831.html" rel="external">algorithm 1</a>) [<a href="#rid8">8,9</a>]. Key features of these criteria include upper and lower motor neuron signs and progression of symptoms over time. The El Escorial criteria have been validated pathologically [<a href="#rid10">10</a>].</p><p>The revised El Escorial criteria were designed for research purposes to ensure appropriate inclusion of patients into clinical trials and allow assignment of diagnostic certainty. They were further adapted (the Awaji criteria) to better incorporate electromyography information and improve diagnostic sensitivity [<a href="#rid11">11</a>]. Based on diagnostic certainty of the clinical evaluation, patients may be categorized as having "definite ALS," "probable ALS," or "possible ALS." However, the complexity and moderate inter-rater reliability when applying these criteria have been criticized [<a href="#rid12">12,13</a>]. Additionally, categories of diagnostic certainty do not necessarily predict disease progression [<a href="#rid14">14,15</a>].</p><p>Consensus diagnostic criteria were proposed in 2019 to address these concerns and simplify the diagnosis [<a href="#rid16">16</a>]. These simplified diagnostic criteria (termed "Gold Coast criteria") for ALS include:</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive upper and lower motor neuron symptoms and signs in one limb or body segment, OR</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progressive lower motor neuron symptoms and signs in at least two body segments, AND</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of electrophysiologic, neuroimaging, and pathologic evidence of other disease processes that might explain the signs of lower and/or upper motor neuron degeneration</p><p></p><p>An advantage of the Gold Coast criteria is the establishment of the diagnosis of ALS for patients with isolated lower motor neuron signs. It also establishes the diagnosis for patients who would be labeled with "possible ALS" by the El Escorial criteria. This represents a simplification of the diagnostic process without the likelihood of excluding patients with the disease.</p><p>In a retrospective study of 506 patients with suspected ALS, the diagnostic sensitivity of the Gold Coast criteria was similar to the revised El Escorial and Awaji criteria for definite, probable, or possible ALS (92 versus 90 and 89 percent, respectively) [<a href="#rid17">17</a>]. The Gold Coast criteria was more sensitive than the revised El Escorial or Awaji criteria for definite or probable ALS, including those with lower limb and bulbar-onset ALS. The specificity was similar among the three criteria.</p><p class="headingAnchor" id="H2160496378"><span class="h2">Related forms of ALS</span><span class="headingEndMark"> — </span>The clinical evaluation of patients with signs and symptoms of motor neuron disease may suggest the diagnosis of a related form of motor neuron disease in patients who do not meet diagnostic criteria for ALS. In some of these patients, the evolution of symptoms may eventually progress to meet diagnostic criteria for ALS; in others, symptoms remain consistent with a more restricted phenotype of motor neuron disease. These related forms of motor neuron disease include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progressive muscular atrophy</strong> – This progressive disorder is clinically limited to lower motor neurons. If two regions of the body are involved clinically or electrophysiologically, then ALS can be diagnosed based on Gold Coast criteria. If upper motor neuron signs appear over time, the disease is referred to as lower motor neuron–onset ALS. (See  <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease", section on 'Progressive muscular atrophy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary lateral sclerosis</strong> – This is a progressive disorder that is clinically limited to the upper motor neurons. Consensus diagnostic criteria for primary lateral sclerosis require presence of exclusively upper motor neuron signs in at least two of three body regions (bulbar, upper extremity, lower extremity) and the absence of both sensory symptoms and lower motor neuron dysfunction. Duration of progressive symptoms should be for at least four years since symptom onset [<a href="#rid15">15</a>]. If lower motor neuron signs appear before this time, then the diagnosis converts to upper motor neuron–onset ALS. (See  <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease", section on 'Primary lateral sclerosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progressive bulbar palsy</strong> – This is a progressive motor neuron disorder of cranial muscles. When both upper and lower motor neuron findings are present, the disorder meets Gold Coast criteria for the diagnosis of ALS. In nearly all cases, upper and/or lower motor neuron abnormalities will eventually spread to limb, axial, and/or respiratory motor neurons, and these patients may meet criteria for ALS. In this circumstance, the designation is changed to bulbar-onset ALS. (See  <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease", section on 'Progressive bulbar palsy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flail arm (or leg) syndrome</strong> – This syndrome presents with progressive lower motor neuron weakness of the arms. Similarly, flail leg syndrome involves lower motor neuron weakness of the legs. When both arms or both legs are involved, this is similar to progressive muscular atrophy, as described above, and can be called ALS. (See  <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease", section on 'Flail arm syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ALS-plus syndrome</strong> – This is the designation for patients who meet the clinical criteria for ALS and also have features of other disorders that have historically excluded the diagnosis of ALS, such as autonomic insufficiency, extrapyramidal features, supranuclear gaze paresis, and cerebellar ataxia. (See  <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease", section on 'ALS-plus syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H2863228350"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H6"><span class="h2">Electrodiagnostic studies</span><span class="headingEndMark"> — </span>We recommend electrodiagnostic testing with nerve conduction studies and electromyography (EMG) in all patients with suspected ALS. While ALS is primarily a clinical diagnosis, sensory and motor nerve conduction studies and EMG are a standard part of the evaluation of motor neuron disease. Electrodiagnostic studies are most helpful when clinical evidence supporting the diagnosis of ALS is limited or conflicting.</p><p></p><p class="headingAnchor" id="H2904856050"><span class="h3">Electrodiagnostic criteria</span><span class="headingEndMark"> — </span>The following principles have been emphasized regarding electrodiagnostic evidence of lower motor neuron disease in patients with suspected ALS [<a href="#rid18">18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In general, the electrodiagnostic evaluation includes multiple motor and sensory conduction studies in two or more limbs and needle examination of multiple muscles in three limbs, the midthoracic paraspinal region, and the bulbar region.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Motor conduction block should be absent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Motor conduction velocities should be normal in the arm and leg. However, loss of motor axons with resulting reduction of the compound muscle action potential (CMAP) amplitude may be associated with mild slowing of conduction velocity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sensory amplitudes and velocities in the arm and leg should be normal or preserved in relationship to motor amplitudes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of acute or ongoing muscle denervation, as indicated by the presence of fibrillation potentials and positive sharp waves, should be present in multiple muscles of the regions examined. Per the Awaji Island consensus criteria, fasciculations are considered indicative of an acute or ongoing denervation in muscles demonstrating evidence of chronic denervation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of chronic denervation and reinnervation should be present in multiple muscles in one or more limbs and may also be present in bulbar and thoracic muscles.</p><p></p><p class="headingAnchor" id="H7"><span class="h3">Electromyography</span><span class="headingEndMark"> — </span>The EMG findings in ALS combine features of acute and chronic denervation and reinnervation [<a href="#rid19">19,20</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Acute denervation findings include fibrillations and positive sharp waves. The Awaji Island criteria [<a href="#rid21">21</a>] allowed fasciculations in muscles with neurogenic change to be considered equivalent to fibrillations and positive sharp waves.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fasciculation potentials may appear in denervated muscle and represent spontaneous firing of motor units that are not voluntarily recruited. Fasciculations may be visible to the naked eye when they occur on the surface of muscles  (<a class="graphic graphic_movie graphicRef66062" href="/z/d/graphic/66062.html" rel="external">movie 1</a> and <a class="graphic graphic_movie graphicRef63510" href="/z/d/graphic/63510.html" rel="external">movie 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic denervation and reinnervation findings include large-amplitude, long-duration, complex motor unit action potentials (MUAPs) with neurogenic recruitment and a reduced interference pattern. Instability of MUAPs indicative of recent reinnervation is considered an important indication of ongoing denervation and reinnervation by the Awaji criteria.</p><p></p><p>The EMG abnormalities noted in muscles of patients with ALS are not pathognomonic for the disease but can be seen in any disease causing chronic and ongoing denervation. However, the diagnosis of ALS should be suggested by the observation of similar abnormalities in multiple muscles of proximal and distal limbs, in the absence of radiologic demonstration of corresponding nerve root compression considered significant enough to cause the abnormality.</p><p class="headingAnchor" id="H8"><span class="h3">Nerve conduction studies</span><span class="headingEndMark"> — </span>Sensory and motor nerve conduction studies are most often normal in ALS, though CMAP amplitudes may be reduced in severely atrophic and denervated muscles [<a href="#rid19">19,20,22</a>].</p><p>Motor unit number estimation is a nerve conduction-based method that assesses the number of viable motor axons innervating small hand or foot muscles [<a href="#rid23">23</a>]. Although this technique has applications to many diseases, it has been applied most successfully to ALS [<a href="#rid23">23-26</a>]. Motor unit numbers drop prior to the onset of clinical weakness, and changes in this measure can be used as an outcome measure in clinical trials [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H4270015811"><span class="h3">Other electrodiagnostic techniques</span><span class="headingEndMark"> — </span>In addition to routine nerve conduction studies and electromyography, other electrodiagnostic techniques may be performed in select patients being evaluated for ALS. These studies can improve the diagnostic yield of testing and may help identify or exclude alternative diagnoses. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repetitive nerve stimulation</strong> – Repetitive nerve stimulation is a nerve conduction technique that assesses the integrity of the neuromuscular junction and is useful for the diagnosis of disorders such as myasthenia gravis and the Lambert-Eaton myasthenic syndrome [<a href="#rid27">27,28</a>]. Thus, repetitive nerve stimulation may be useful if these conditions are a consideration in the differential diagnosis during the evaluation of suspected motor neuron disease.</p><p></p><p class="bulletIndent1">Repetitive nerve stimulation may be normal or abnormal in patients with ALS, since the physiology of ongoing denervation with reinnervation can cause unstable transmission through the neuromuscular junction, which manifests as an abnormal decrement in the CMAP amplitude [<a href="#rid29">29-35</a>]. Occasionally, the presence of a decrement on repetitive stimulation can cause diagnostic confusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single-fiber EMG</strong> – Single-fiber EMG is used to measure jitter (an evaluation of neuromuscular junction function) and fiber density (an electrophysiologic assessment of reinnervation following denervation). Jitter may be abnormally increased in the presence of ongoing reinnervation and newly formed, unstable neuromuscular junctions [<a href="#rid19">19,36</a>].</p><p></p><p class="bulletIndent1">Increased fiber density is a nonspecific finding that may be present in any muscle that has undergone denervation and reinnervation. Collateral sprouting increases the number of muscle fibers within the territory of reinnervated motor units. As a result, adjacent muscle fibers within any region of a denervated/reinnervated muscle are more likely to be part of the same motor unit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transcranial magnetic stimulation</strong> – External stimulation with a magnet over the motor cortex, cervical spine, and lumbosacral spine produces a CMAP that can be recorded from the surface. The difference between the latency of the response elicited by cranial versus cervical or cranial versus lumbosacral stimulation is called the central motor conduction time and is a reflection of the integrity of central motor pathways. Slowing of central motor conduction time has been reported in patients with ALS. Another measure, cortical hyperexcitability, may be an early and specific feature of ALS [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1">Transcranial magnetic stimulation (TMS) remains a largely experimental technique and is not used or routinely available for clinical diagnosis. However, correlation with clinical upper motor neuron signs has been noted [<a href="#rid38">38-45</a>]. One preliminary study found that the TMS threshold tracking technique to detect cortical hyperexcitability in patients with suspected ALS had a reasonable sensitivity and specificity (73 and 81 percent, respectively) to distinguish ALS from non-ALS disorders at an early stage of disease [<a href="#rid46">46</a>]. In work by the same group, the addition of a range of TMS and EMG parameters to clinical criteria to generate an ALS diagnostic index (ALSDI) improved diagnostic accuracy for early ALS compared with the Awaji criteria [<a href="#rid47">47</a>]. If further validated, tools like the ALSDI may help to improve the certainty with which clinicians can differentiate ALS from mimics at an early stage of disease, when new therapies are most likely to be effective [<a href="#rid48">48</a>].</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Additional diagnostic studies</span><span class="headingEndMark"> — </span>We recommend neuroimaging and routine laboratory testing in all patients with suspected ALS to exclude alternative diagnoses. Other diagnostic testing is performed for selected patients. There is no single diagnostic test that can confirm or entirely exclude the diagnosis of motor neuron disease. However, neuroimaging and laboratory studies are often important to exclude alternative diagnoses.</p><p class="headingAnchor" id="H15"><span class="h3">Neuroimaging</span><span class="headingEndMark"> — </span>Neuroimaging has traditionally been used to exclude other possible diagnoses in the evaluation of suspected ALS. Magnetic resonance imaging (MRI) is the preferred modality, unless there is a contraindication. Brain MRI should be performed whenever bulbar disease is present. Cervical and lumbosacral spine MRI can be used to evaluate lower motor neuron findings in the arms and legs.</p><p>When evaluating upper motor neuron findings, MRI should be performed in all segments rostral to the clinical findings; this includes the brain, cervical spine, and thoracic spine when upper motor neuron findings are in the legs. Conventional MRI is usually normal in ALS, although increased signal in the corticospinal tracts on T2-weighted and fluid-attenuated inversion recovery images and hypointensity of the motor cortex on both T2-weighted and T2*-susceptibility-weighted images may be seen [<a href="#rid49">49-53</a>].</p><p>Experimental imaging techniques to detect upper motor neuron disease in ALS include magnetic resonance spectroscopy and diffusion tensor imaging [<a href="#rid54">54-57</a>]. Magnetic resonance spectroscopy provides biochemical and metabolic information in the form of a spectrum obtained in a region of interest or in the whole brain. The three major peaks observed on an in vivo proton magnetic resonance spectrum are from N-acetyl aspartate (NAA), choline (Cho), and creatine (Cr). NAA is thought to correlate with neuronal integrity. The data are presented either quantitatively or as ratios.</p><p>The balance of evidence has shown reduced NAA levels or lower ratios of NAA:Cr, NAA:Cho, or NAA:Cr+Cho in the motor cortex and corticospinal tract of patients with ALS [<a href="#rid55">55,56,58,59</a>]. Correlation with clinical parameters was not consistently achieved in earlier studies, but one study evaluating whole-brain magnetic resonance spectroscopic imaging found that reductions in NAA along the corticospinal tract correlated with disability [<a href="#rid59">59</a>].</p><p>Diffusion tensor imaging is a structural neuroimaging technique that measures the extent and direction of water diffusion. Diffusion of brain water has been shown to have strong directionality (anisotropy) in white matter [<a href="#rid60">60,61</a>]. Diffusion anisotropy is the result of restricted diffusion of water molecules across myelinated white matter fibers compared with diffusion along the fibers. Patients with ALS have been shown to have decreased fractional anisotropy and increased mean diffusivity in the corticospinal tracts at multiple levels and in the corpus callosum [<a href="#rid54">54,55,62-65</a>].</p><p class="headingAnchor" id="H16"><span class="h3">Laboratory testing</span><span class="headingEndMark"> — </span>Laboratory testing of blood, urine, and sometimes cerebrospinal fluid (CSF) is performed during the evaluation of motor neuron disease. Routine laboratory work usually includes complete blood count with differential, electrolytes including calcium and phosphate, liver function tests, thyroid studies, creatine phosphokinase, erythrocyte sedimentation rate, antinuclear antibody, rheumatoid factor, vitamin B12, anti-GM1 antibody, serum protein electrophoresis with immunofixation, and urine protein electrophoresis with immunofixation.</p><p class="bulletIndent1"><span class="glyph">●</span>In ALS, creatine phosphokinase may be elevated up to approximately 1000 units/L on the basis of denervation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with an elevated serum calcium level, the serum parathyroid hormone level should be checked. ALS is rarely associated with primary hyperparathyroidism [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identification of a serum paraprotein should prompt further work-up with a 24-hour urine protein electrophoresis, a skeletal survey, and computed tomography (CT) of the chest, abdomen, and pelvis to look for myeloma and lymphoma. In such cases, referral to a hematologist/oncologist for bone marrow biopsy may be appropriate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In some cases, testing for Lyme disease may be appropriate in regions where it is endemic (see  <a class="medical medical_review" href="/z/d/html/15247.html" rel="external">"Nervous system Lyme disease"</a>). This is particularly important in the following situations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When the clinical manifestations include radicular or neuropathic pain and/or unilateral peripheral facial palsy</p><p class="bulletIndent2"><span class="glyph">•</span>When sensory signs and symptoms are present</p><p class="bulletIndent2"><span class="glyph">•</span>When MRI of the brain demonstrates multiple white matter signal hyperintensities</p><p class="bulletIndent2"><span class="glyph">•</span>When MRI of the brain and spine demonstrates meningeal signal change and/or enhancement</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testing for HIV may be appropriate, particularly in younger patients, at-risk individuals, and those with atypical features. (See  <a class="medical medical_review" href="/z/d/html/86984.html" rel="external">"Acute and early HIV infection: Clinical manifestations and diagnosis", section on 'Neurologic findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening for heavy metals in the blood and urine is not required if there is no known occupational exposure. Only lead intoxication has been reported to cause a condition resembling lower motor neuron–predominant ALS. This condition has been largely eliminated through monitoring of occupational exposure [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is generally no need to send paraneoplastic antibody panels in patients suspected of having ALS; however, anti-glutamic acid decarboxylase (GAD) antibody testing may be indicated in the setting of significant upper motor neuron disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testing for the antibodies found in myasthenia gravis (acetylcholine receptor antibodies and muscle-specific tyrosine kinase [MuSK] antibodies) and Lambert-Eaton myasthenic syndrome (voltage-gated calcium channel antibodies) is appropriate in the right clinical setting and is particularly appropriate in patients with bulbar dysfunction or any ocular motility disturbance. (See  <a class="medical medical_review" href="/z/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis"</a> and  <a class="medical medical_review" href="/z/d/html/5174.html" rel="external">"Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis", section on 'VGCC antibody testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lumbar puncture and CSF analysis should be performed if there is clinical suspicion for Lyme disease, HIV infection, or chronic inflammatory demyelinating polyneuropathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lumbar puncture for CSF analysis that includes cytology and a search for systemic malignancy should be considered in lower motor neuron disorders with symptoms that have progressed over a period of less than two years. This recommendation is based on our clinical experience and the knowledge that multiple types of cancer can produce a subacutely progressive lower motor disorder by direct infiltration of the meninges, motor roots, and cranial nerves. (See  <a class="medical medical_review" href="/z/d/html/5185.html" rel="external">"Clinical features and diagnosis of leptomeningeal disease from solid tumors"</a>.)</p><p></p><p>Elevated levels of CSF neurofilament are found in patients with ALS, suggesting a possible future role for neurofilament as CSF biomarkers of ALS [<a href="#rid68">68,69</a>].</p><p class="headingAnchor" id="H17"><span class="h3">Genetic testing</span><span class="headingEndMark"> — </span>Genetic testing has not traditionally been a routine part of the diagnostic evaluation in ALS. However, familial ALS (FALS) accounts for approximately 10 percent of all ALS cases. Clinical genetic testing for FALS is available to look for variants in a number of genes, and it is now possible to identify the pathogenic variant in approximately 80 percent of patients with FALS. Autosomal-dominant inheritance is the most common pattern in hereditary ALS. (See  <a class="medical medical_review" href="/z/d/html/5176.html" rel="external">"Familial amyotrophic lateral sclerosis", section on 'Autosomal dominant'</a>.)</p><p>Issues related to genetic testing in ALS are evolving rapidly as clinical trials targeted to certain genetically mediated forms of ALS are becoming a reality. (See  <a class="medical medical_review" href="/z/d/html/5176.html" rel="external">"Familial amyotrophic lateral sclerosis", section on 'Who should be tested?'</a>.)</p><p class="headingAnchor" id="H1104160884"><span class="h3">Neuromuscular ultrasound</span><span class="headingEndMark"> — </span>Limited evidence suggests that the use of muscle ultrasound to detect fasciculations can aid in the diagnosis of ALS. (See  <a class="medical medical_review" href="/z/d/html/14145.html" rel="external">"Diagnostic ultrasound in neuromuscular disease", section on 'Dynamic changes in diseased muscle'</a>.)</p><p>In one prospective unblinded report of 81 patients with sporadic ALS, fasciculations were detected at a significantly higher rate by ultrasound compared with needle EMG in a variety of muscles including the tongue (60 versus 0 percent), biceps brachii (88 versus 66 percent), and tibialis anterior (83 versus 45 percent) [<a href="#rid70">70</a>]. Consequently, the proportion of patients who fulfilled Awaji diagnostic criteria for definite or probable ALS using information from both EMG and ultrasound was modestly higher compared with EMG alone (79 versus 74 percent).</p><p>Another small study found that ultrasound can identify nerve and muscle atrophy in patients with ALS compared with controls, but these findings are recognized as nonspecific because they occur in a variety of neuropathic and myopathic disorders [<a href="#rid71">71</a>].</p><p>Thus, additional research is needed to determine the true utility of neuromuscular ultrasound in the diagnosis of ALS [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H18"><span class="h3">Muscle biopsy</span><span class="headingEndMark"> — </span>Muscle biopsy is not a routine part of the diagnostic evaluation of ALS but may be performed if myopathy is suspected on clinical, electrodiagnostic, or serologic grounds.</p><p>Findings on muscle biopsy in ALS are the nonspecific findings of chronic denervation with reinnervation. Denervated fibers may appear shrunken, angular, and darkly staining. Fiber-type grouping is a prominent finding that reflects reinnervation. Muscle cell type (fast, slow, or intermediate twitch) is determined by the innervating motor neuron and leads to characteristic staining intensities. Normally, different fiber types are distributed randomly within the muscle, leading to a variegated appearance. With reinnervation, the likelihood that adjacent fibers will be innervated by the same motor neuron increases, leading to groups of adjacent fibers having the same staining characteristics.</p><p class="headingAnchor" id="H19"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>A complete evaluation should be aimed at eliminating the possibility that signs or symptoms may be accounted for by an alternative diagnosis  (<a class="graphic graphic_table graphicRef64932" href="/z/d/graphic/64932.html" rel="external">table 5</a>).</p><p class="headingAnchor" id="H20"><span class="h2">Multifocal motor neuropathy</span><span class="headingEndMark"> — </span>Multifocal motor neuropathy (MMN), also known as MMN with conduction block, is characterized by lower motor neuron signs that often present in a bibrachial pattern. (See  <a class="medical medical_review" href="/z/d/html/89904.html" rel="external">"Multifocal motor neuropathy"</a>.)</p><p>The typical clinical presentation of MMN is one of subacute onset with asymmetric weakness and lower motor neuron signs producing arm and hand weakness without associated sensory loss. The neuronal involvement in MMN is typically patchy, with some nerves unaffected and others severely involved. Motor nerve conduction studies usually show evidence of conduction block. Sensory conduction through the same segment of nerve is normal. Elevated titers of anti-GM1 antibodies are present in 30 to 80 percent of patients. (See  <a class="medical medical_review" href="/z/d/html/89904.html" rel="external">"Multifocal motor neuropathy", section on 'Clinical features'</a>.)</p><p>MMN is a particularly important diagnosis to consider as the condition is treatable with intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> and other forms of immunosuppression. (See  <a class="medical medical_review" href="/z/d/html/89904.html" rel="external">"Multifocal motor neuropathy", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Cervical radiculomyelopathy</span><span class="headingEndMark"> — </span>Cervical spondylosis with nerve root compression can cause the combination of lower motor neuron signs at the level of abnormality with upper motor neuron signs below it. This condition often includes dermatomal or distal sensory abnormalities and sphincter dysfunction, but these features may be absent. Cervical magnetic resonance imaging (MRI) establishes the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/4820.html" rel="external">"Cervical spondylotic myelopathy"</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Benign fasciculations</span><span class="headingEndMark"> — </span>Spontaneous fasciculations may occur in up to 70 percent of people [<a href="#rid73">73</a>]. A smaller proportion of this group will experience relatively frequent fasciculations that may be widespread or relatively focal and may be accompanied by cramps. Long-term follow-up of patients with excess fasciculations who have a normal examination and normal electromyography (EMG) suggests that this is a truly benign condition and does not confer an increased risk for the development of motor neuron disease [<a href="#rid74">74-76</a>]. (See  <a class="medical medical_review" href="/z/d/html/5145.html" rel="external">"Overview of electromyography", section on 'Fasciculations'</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Inflammatory myopathies</span><span class="headingEndMark"> — </span>Polymyositis, dermatomyositis, immune-mediated necrotizing myopathy, overlap syndromes with rheumatologic disease, antisynthetase syndromes, and inclusion body myopathy comprise the inflammatory myopathies. Weakness of voluntary muscles and dysphagia along with elevated levels of creatine phosphokinase may occur in each of these conditions. However, inflammatory myopathies may also present with skin findings, interstitial lung disease, and arthralgias. Muscle biopsy and antibody testing is usually required for diagnosis of these disorders. Electrophysiologic findings consistent with myopathy are often seen, but motor unit morphology and recruitment in end-stage myopathy can appear similar to findings characteristic of chronic denervation. (See  <a class="medical medical_review" href="/z/d/html/127066.html" rel="external">"Overview of and approach to the idiopathic inflammatory myopathies"</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Post-polio syndrome</span><span class="headingEndMark"> — </span>Post-polio syndrome is a condition that occurs many years after partial or full clinical recovery from viral poliomyelitis. It is characterized by neurologic and musculoskeletal complaints. Progressive weakness with or without atrophy may occur in segments that were affected at the time of initial infection. Upper motor neuron signs do not occur. The condition may also include pain in muscles or joints and generalized fatigue. The diagnosis of post-polio syndrome is clinical and is based on slow progression of the above clinical findings [<a href="#rid77">77,78</a>]. (See  <a class="medical medical_review" href="/z/d/html/5143.html" rel="external">"Poliomyelitis and post-polio syndrome", section on 'Post-polio syndrome'</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Monomelic amyotrophy</span><span class="headingEndMark"> — </span>Monomelic amyotrophy, also known as focal amyotrophy, is a condition that presents clinically with early onset of focal atrophy and weakness, most commonly of a single hand and arm and rarely of a leg.</p><p>One form of monomelic amyotrophy known as Hirayama disease progresses over one to five years (less commonly over eight years) and then plateaus [<a href="#rid67">67,79-84</a>]. Cervical spine MRI in the neutral and flexed positions characteristically shows asymmetric flattening of the cord in the neutral position, anterior displacement of the dura during flexion, and a prominent posterior epidural venous plexus [<a href="#rid85">85-87</a>]. The proposed mechanism is repeated transient ischemia of the spinal cord due to forward displacement of the dura on the cord with neck flexion [<a href="#rid88">88</a>]. Some patients with monomelic amyotrophy have generalized joint hypermobility that may contribute to excessive cervical joint flexion and extension [<a href="#rid89">89</a>]. Management is controversial. While most opt for clinical observation, use of a cervical collar and surgical decompression with fusion have been described in the literature.</p><p>Another form of self-limited arm weakness, known as the O'Sullivan–McLeod syndrome, progresses over a longer period of 25 to 40 years [<a href="#rid90">90</a>].</p><p>Both Hirayama disease and O'Sullivan–McLeod syndrome are male-predominant disorders that affect one or occasionally both upper extremities with weakness that is distal (90 percent) more commonly than proximal (10 percent). Recovery does not occur, but both conditions are considered to be benign since they do not progress to systemic motor neuron disease [<a href="#rid67">67,91-93</a>].</p><p>While usually sporadic, familial cases of upper-extremity monomelic amyotrophy have been reported [<a href="#rid80">80,84,94-96</a>].</p><p>Lower-extremity monomelic amyotrophy is much less common. It is male predominant with weakness that is most often present asymmetrically in the gastrocnemius, peronei, and hamstrings more commonly than in the quadriceps. Progression occurs over a few years and is followed by a clinical plateau [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H27"><span class="h2">Hereditary spastic paraplegia</span><span class="headingEndMark"> — </span>Hereditary spastic paraplegia is a large group of inherited neurologic disorders in which the prominent feature is a progressive upper motor neuron spastic weakness of the legs that is similar to that seen in ALS and primary lateral sclerosis. However, unlike those conditions, patients with hereditary spastic paraplegia often have urinary urgency and high arched feet. Some forms of hereditary spastic paraplegia may be associated with cerebellar dysfunction, optic atrophy, and peripheral neuropathy (SPG7) or with cognitive decline, upper-extremity weakness, dysarthria, nystagmus, and thinning of the corpus callosum on MRI (SPG11). (See  <a class="medical medical_review" href="/z/d/html/5093.html" rel="external">"Disorders affecting the spinal cord", section on 'Hereditary spastic paraplegias'</a>.)</p><p class="headingAnchor" id="H3995356"><span class="h2">Spinobulbar muscular atrophy</span><span class="headingEndMark"> — </span>An expansion of an unstable cytosine-adenine-guanine (CAG) tandem repeat in exon 1 of the androgen receptor gene on chromosome Xq11-12 occurs in males with spinobulbar muscular atrophy (also known as Kennedy disease) [<a href="#rid97">97</a>]. This X-linked disorder is characterized by onset from ages 20 to 60 years of slowly progressive weakness and atrophy affecting facial, bulbar, and limb muscles that may be predominantly asymmetric, symmetric, proximal, or distal. There is degeneration of lower motor neurons in brainstem nuclei and spinal cord. Associated endocrine disturbances include late-onset gynecomastia, defective spermatogenesis, and a hormonal profile consistent with androgen resistance. The androgen receptor gene contains an expansion in the number of glutamine repeats in the N-terminal region  (<a class="graphic graphic_figure graphicRef61536" href="/z/d/graphic/61536.html" rel="external">figure 1</a>) from the usual 20 glutamines to &gt;40 repeats [<a href="#rid98">98</a>]. The pathogenesis is not fully understood, but accumulating evidence suggests that neuronal degeneration and death are related to accumulation of the toxic expanded androgen receptor [<a href="#rid97">97</a>].</p><p class="headingAnchor" id="H28"><span class="h2">Myasthenia gravis</span><span class="headingEndMark"> — </span>Myasthenia gravis occasionally can present as a bulbar syndrome with dysphagia and dysarthria but without the ptosis or ocular motility disturbance that commonly accompanies myasthenia. This presentation can mimic bulbar-onset ALS. The absence of upper or lower motor neuron bulbar signs, the presence of ocular findings, and a history of diurnal variation of symptoms weigh in favor of myasthenia gravis. In addition, it is more common for myasthenia to present with ptosis and ocular dysmotility, in which case it is unlikely to be confused with bulbar ALS. (See  <a class="medical medical_review" href="/z/d/html/5170.html" rel="external">"Clinical manifestations of myasthenia gravis"</a>.)</p><p>Testing for acetylcholine receptor-binding antibodies should be performed on all patients if myasthenia gravis is suspected. Testing for muscle-specific tyrosine kinase (MuSK) antibodies should be pursued if acetylcholine receptor antibodies are negative. The diagnosis of myasthenia gravis is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis"</a>.)</p><p>Repetitive nerve stimulation and single-fiber EMG of facial muscles may be abnormal in both myasthenia gravis and bulbar-onset ALS with lower motor neuron facial weakness. Cranial muscles such as the tongue, masseter, or sternocleidomastoid will demonstrate electrophysiologic evidence of denervation and reinnervation in bulbar-onset ALS. (See <a class="local">'Other electrodiagnostic techniques'</a> above.)</p><p class="headingAnchor" id="H29"><span class="h2">Hyperthyroidism</span><span class="headingEndMark"> — </span>There is no evidence of an association between hyperthyroidism and motor neuron disease. However, clinical features in patients with thyrotoxicosis may include upper motor neuron signs related to pyramidal tract dysfunction and lower motor neuron signs related to a peripheral neuropathy; these may overlap with those of ALS. (See  <a class="medical medical_review" href="/z/d/html/4836.html" rel="external">"Neurologic manifestations of hyperthyroidism and Graves' disease", section on 'Motor neuron manifestations'</a>.)</p><p class="headingAnchor" id="H65629974"><span class="h2">Others</span><span class="headingEndMark"> — </span>Other conditions to consider in the differential diagnosis of ALS  (<a class="graphic graphic_table graphicRef64932" href="/z/d/graphic/64932.html" rel="external">table 5</a>) include the following [<a href="#rid99">99</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Adult-onset spinal muscular atrophy</p><p class="bulletIndent1"><span class="glyph">●</span>Late-onset Tay-Sachs disease (GM2 gangliosidosis)</p><p class="bulletIndent1"><span class="glyph">●</span>Motor neuron syndromes with lymphoproliferative disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Motor neuron syndromes in lung, breast, and other cancers</p><p class="bulletIndent1"><span class="glyph">●</span>Radiation brainstem injury/radiation myelopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Intraspinal lesions (eg, syringomyelia, syringobulbia, or tumor)</p><p></p><p>Lymphoma, lung cancer, and breast cancer can produce an indirect paraneoplastic degeneration of the motor neurons that is most commonly subacute to chronic. (See  <a class="medical medical_review" href="/z/d/html/5190.html" rel="external">"Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle", section on 'Subacute motor neuronopathy'</a>.)</p><p class="headingAnchor" id="H1702277535"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118906.html" rel="external">"Society guideline links: Motor neuron disease"</a>.)</p><p class="headingAnchor" id="H248869334"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86016.html" rel="external">"Patient education: Amyotrophic lateral sclerosis (ALS) (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H4025022396"><span class="h1">PATIENT PERSPECTIVE TOPIC</span><span class="headingEndMark"> — </span>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/z/d/html/139137.html" rel="external">"Patient perspective: Amyotrophic lateral sclerosis (ALS)"</a>.)</p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Key clinical features</strong> – Clinical manifestations of amyotrophic lateral sclerosis (ALS) include the presence of upper motor neuron and lower motor neuron signs, progression of disease, and the absence of an alternative explanation. Motor impairment may involve limb  (<a class="graphic graphic_table graphicRef72454" href="/z/d/graphic/72454.html" rel="external">table 1</a>), bulbar  (<a class="graphic graphic_table graphicRef75146" href="/z/d/graphic/75146.html" rel="external">table 2</a>), axial  (<a class="graphic graphic_table graphicRef67913" href="/z/d/graphic/67913.html" rel="external">table 3</a>), and respiratory  (<a class="graphic graphic_table graphicRef58537" href="/z/d/graphic/58537.html" rel="external">table 4</a>) function. Cognitive change related to frontotemporal dysfunction may be the presenting symptom in a small subset of patients. (See <a class="local">'Clinical evaluation'</a> above and  <a class="medical medical_review" href="/z/d/html/5136.html" rel="external">"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of ALS is made in patients who meet diagnostic criteria assessed by history and physical examination, supported by electrodiagnostic studies, and not excluded by neuroimaging and laboratory studies. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">The criteria used for the diagnosis of ALS have evolved over time. The revised El Escorial World Federation of Neurology criteria, also known as the Airlie House criteria, include upper and lower motor neuron signs and progression of symptoms over time  (<a class="graphic graphic_algorithm graphicRef62831" href="/z/d/graphic/62831.html" rel="external">algorithm 1</a>) [<a href="#rid8">8,9</a>]. The Gold Coast criteria simplify the revised El Escorial criteria for ALS. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrodiagnostic studies</strong> – We recommend electrodiagnostic testing with nerve conduction studies and electromyography (EMG) in all patients with suspected ALS. Sensory and motor nerve conduction studies are most often normal in ALS, although compound muscle action potential (CMAP) amplitudes may be reduced in severely atrophic and denervated muscles. EMG typically reveals combined features of acute and chronic denervation in ALS. (See <a class="local">'Electrodiagnostic studies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional diagnostic testing</strong> – We recommend neuroimaging and routine laboratory testing in all patients with suspected ALS to exclude alternative diagnoses. Other diagnostic testing is performed for selected patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neuroimaging</strong> – Magnetic resonance imaging (MRI) evaluation should include all segments rostral to the clinical findings; this includes the brain, cervical spine, and thoracic spine when upper motor neuron findings are in the legs. Conventional MRI is usually normal in ALS. (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Routine laboratory testing</strong> – Routine testing of blood and urine is used for all patients to exclude alternative diagnoses. Lumbar puncture for cerebrospinal fluid analysis is performed if there is clinical suspicion for the diagnosis of chronic inflammatory demyelinating polyneuropathy, Lyme disease, HIV infection, or lymphoma or if there is a rapidly progressive isolated lower motor neuron syndrome. Additional laboratory testing may be required in certain clinical settings. (See <a class="local">'Laboratory testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other testing for some patients</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Genetic testing is not a required part of the diagnostic evaluation in ALS but can be helpful in making the diagnosis in familial ALS, which accounts for approximately 10 percent of all ALS cases. (See <a class="local">'Genetic testing'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Muscle biopsy is not a routine part of the diagnostic evaluation of ALS but should be performed if there is clinical suspicion of inflammatory myopathy. (See <a class="local">'Muscle biopsy'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of ALS is extensive  (<a class="graphic graphic_table graphicRef64932" href="/z/d/graphic/64932.html" rel="external">table 5</a>). This includes multifocal motor neuropathy, cervical radiculomyelopathy, benign fasciculations, inflammatory myopathies, post-polio syndrome, monomelic amyotrophy, hereditary spastic paraplegia, spinobulbar muscular atrophy, myasthenia gravis, and hyperthyroidism. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lomen-Hoerth C. Characterization of amyotrophic lateral sclerosis and frontotemporal dementia. Dement Geriatr Cogn Disord 2004; 17:337.</a></li><li><a class="nounderline abstract_t">Strong MJ, Lomen-Hoerth C, Caselli RJ, et al. Cognitive impairment, frontotemporal dementia, and the motor neuron diseases. Ann Neurol 2003; 54 Suppl 5:S20.</a></li><li><a class="nounderline abstract_t">Lomen-Hoerth C, Murphy J, Langmore S, et al. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003; 60:1094.</a></li><li><a class="nounderline abstract_t">Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002; 59:1077.</a></li><li class="breakAll">Mitsumoto H, Chad DA, Pioro EP. Amyotrophic lateral sclerosis. In: Contemporary Neurology Series, 49, FA Davis Company, 1998.</li><li><a class="nounderline abstract_t">LANDAU WM, CLARE MH. The plantar reflex in man, with special reference to some conditions where the extensor response is unexpectedly absent. Brain 1959; 82:321.</a></li><li><a class="nounderline abstract_t">Feldman EL, Goutman SA, Petri S, et al. Amyotrophic lateral sclerosis. Lancet 2022; 400:1363.</a></li><li><a class="nounderline abstract_t">Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 1994; 124 Suppl:96.</a></li><li><a class="nounderline abstract_t">Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1:293.</a></li><li><a class="nounderline abstract_t">Chaudhuri KR, Crump S, al-Sarraj S, et al. The validation of El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis: a clinicopathological study. J Neurol Sci 1995; 129 Suppl:11.</a></li><li><a class="nounderline abstract_t">Boekestein WA, Kleine BU, Hageman G, et al. Sensitivity and specificity of the 'Awaji' electrodiagnostic criteria for amyotrophic lateral sclerosis: retrospective comparison of the Awaji and revised El Escorial criteria for ALS. Amyotroph Lateral Scler 2010; 11:497.</a></li><li><a class="nounderline abstract_t">Forbes RB, Colville S, Swingler RJ. Are the El Escorial and Revised El Escorial criteria for ALS reproducible? A study of inter-observer agreement. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2:135.</a></li><li><a class="nounderline abstract_t">Johnsen B, Pugdahl K, Fuglsang-Frederiksen A, et al. Diagnostic criteria for amyotrophic lateral sclerosis: A multicentre study of inter-rater variation and sensitivity. Clin Neurophysiol 2019; 130:307.</a></li><li><a class="nounderline abstract_t">Traynor BJ, Codd MB, Corr B, et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol 2000; 57:1171.</a></li><li><a class="nounderline abstract_t">Turner MR, Barohn RJ, Corcia P, et al. Primary lateral sclerosis: consensus diagnostic criteria. J Neurol Neurosurg Psychiatry 2020; 91:373.</a></li><li><a class="nounderline abstract_t">Shefner JM, Al-Chalabi A, Baker MR, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol 2020; 131:1975.</a></li><li><a class="nounderline abstract_t">Hannaford A, Pavey N, van den Bos M, et al. Diagnostic Utility of Gold Coast Criteria in Amyotrophic Lateral Sclerosis. Ann Neurol 2021; 89:979.</a></li><li class="breakAll">Shefner JM. Amyotrophic lateral sclerosis. In: Office Practice of Neurology, 2nd ed, Samuels MA, Feske SK (Eds), Churchill Livingstone, 2003. p.548.</li><li><a class="nounderline abstract_t">Daube JR. Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle Nerve 2000; 23:1488.</a></li><li><a class="nounderline abstract_t">Krivickas LS. Amyotrophic lateral sclerosis and other motor neuron diseases. Phys Med Rehabil Clin N Am 2003; 14:327.</a></li><li><a class="nounderline abstract_t">Costa J, Swash M, de Carvalho M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis:a systematic review. Arch Neurol 2012; 69:1410.</a></li><li><a class="nounderline abstract_t">de Carvalho M, Swash M. Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve 2000; 23:344.</a></li><li><a class="nounderline abstract_t">Olney RK, Lomen-Hoerth C. Motor unit number estimation (MUNE): how may it contribute to the diagnosis of ALS? Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1 Suppl 2:S41.</a></li><li><a class="nounderline abstract_t">Shefner JM, Gooch CL. Motor unit number estimation in neurologic disease. Adv Neurol 2002; 88:33.</a></li><li><a class="nounderline abstract_t">Gooch CL, Shefner JM. ALS surrogate markers. MUNE. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5 Suppl 1:104.</a></li><li><a class="nounderline abstract_t">de Carvalho M, Scotto M, Lopes A, Swash M. Quantitating progression in ALS. Neurology 2005; 64:1783.</a></li><li><a class="nounderline abstract_t">LAMBERT EH, MULDER DW. Electromyographic studies in amyotrophic lateral sclerosis. Proc Staff Meet Mayo Clin 1957; 32:441.</a></li><li><a class="nounderline abstract_t">MULDER DW, LAMBERT EH, EATON LM. Myasthenic syndrome in patients with amyotrophic lateral sclerosis. Neurology 1959; 9:627.</a></li><li><a class="nounderline abstract_t">Henderson RD, Daube JR. Decrement in surface-recorded motor unit potentials in amyotrophic lateral sclerosis. Neurology 2004; 63:1670.</a></li><li><a class="nounderline abstract_t">Jillapalli D, Shefner JM. Single motor unit variability with threshold stimulation in patients with amyotrophic lateral sclerosis and normal subjects. Muscle Nerve 2004; 30:578.</a></li><li><a class="nounderline abstract_t">Wang FC, De Pasqua V, Gérard P, Delwaide PJ. Prognostic value of decremental responses to repetitive nerve stimulation in ALS patients. Neurology 2001; 57:897.</a></li><li><a class="nounderline abstract_t">Killian JM, Wilfong AA, Burnett L, et al. Decremental motor responses to repetitive nerve stimulation in ALS. Muscle Nerve 1994; 17:747.</a></li><li><a class="nounderline abstract_t">Denys EH, Norris FH Jr. Amyotrophic lateral sclerosis. Impairment of neuromuscular transmission. Arch Neurol 1979; 36:202.</a></li><li><a class="nounderline abstract_t">Brown WF, Jaatoul N. Amyotrophic lateral sclerosis. Electrophysiologic study (number of motor units and rate of decay of motor units). Arch Neurol 1974; 30:242.</a></li><li><a class="nounderline abstract_t">Carleton SA, Brown WF. Changes in motor unit populations in motor neurone disease. J Neurol Neurosurg Psychiatry 1979; 42:42.</a></li><li><a class="nounderline abstract_t">Cui LY, Liu MS, Tang XF. Single fiber electromyography in 78 patients with amyotrophic lateral sclerosis. Chin Med J (Engl) 2004; 117:1830.</a></li><li><a class="nounderline abstract_t">Vucic S, Cheah BC, Yiannikas C, Kiernan MC. Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol 2011; 122:1860.</a></li><li><a class="nounderline abstract_t">de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008; 119:497.</a></li><li><a class="nounderline abstract_t">Pohl C, Block W, Träber F, et al. Proton magnetic resonance spectroscopy and transcranial magnetic stimulation for the detection of upper motor neuron degeneration in ALS patients. J Neurol Sci 2001; 190:21.</a></li><li><a class="nounderline abstract_t">Schulte-Mattler WJ, Müller T, Zierz S. Transcranial magnetic stimulation compared with upper motor neuron signs in patients with amyotrophic lateral sclerosis. J Neurol Sci 1999; 170:51.</a></li><li><a class="nounderline abstract_t">Kaufmann P, Mitsumoto H. Amyotrophic lateral sclerosis: objective upper motor neuron markers. Curr Neurol Neurosci Rep 2002; 2:55.</a></li><li><a class="nounderline abstract_t">Kaufmann P, Pullman SL, Shungu DC, et al. Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology 2004; 62:1753.</a></li><li><a class="nounderline abstract_t">Pouget J, Trefouret S, Attarian S. Transcranial magnetic stimulation (TMS): compared sensitivity of different motor response parameters in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1 Suppl 2:S45.</a></li><li><a class="nounderline abstract_t">Miscio G, Pisano F, Mora G, Mazzini L. Motor neuron disease: usefulness of transcranial magnetic stimulation in improving the diagnosis. Clin Neurophysiol 1999; 110:975.</a></li><li><a class="nounderline abstract_t">Floyd AG, Yu QP, Piboolnurak P, et al. Transcranial magnetic stimulation in ALS: utility of central motor conduction tests. Neurology 2009; 72:498.</a></li><li><a class="nounderline abstract_t">Menon P, Geevasinga N, Yiannikas C, et al. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol 2015; 14:478.</a></li><li><a class="nounderline abstract_t">Geevasinga N, Howells J, Menon P, et al. Amyotrophic lateral sclerosis diagnostic index: Toward a personalized diagnosis of ALS. Neurology 2019; 92:e536.</a></li><li><a class="nounderline abstract_t">Lacomis D, Gooch C. Upper motor neuron assessment and early diagnosis in ALS: Getting it right the first time. Neurology 2019; 92:255.</a></li><li><a class="nounderline abstract_t">Chan S, Shungu DC, Douglas-Akinwande A, et al. Motor neuron diseases: comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain. Radiology 1999; 212:763.</a></li><li><a class="nounderline abstract_t">Oba H, Araki T, Ohtomo K, et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology 1993; 189:843.</a></li><li><a class="nounderline abstract_t">Cosottini M, Donatelli G, Ricca I, et al. Iron-sensitive MR imaging of the primary motor cortex to differentiate hereditary spastic paraplegia from other motor neuron diseases. Eur Radiol 2022; 32:8058.</a></li><li><a class="nounderline abstract_t">Roeben B, Wilke C, Bender B, et al. The motor band sign in ALS: presentations and frequencies in a consecutive series of ALS patients. J Neurol Sci 2019; 406:116440.</a></li><li><a class="nounderline abstract_t">Adachi Y, Sato N, Saito Y, et al. Usefulness of SWI for the Detection of Iron in the Motor Cortex in Amyotrophic Lateral Sclerosis. J Neuroimaging 2015; 25:443.</a></li><li><a class="nounderline abstract_t">Turner MR, Grosskreutz J, Kassubek J, et al. Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol 2011; 10:400.</a></li><li><a class="nounderline abstract_t">Wang S, Melhem ER, Poptani H, Woo JH. Neuroimaging in amyotrophic lateral sclerosis. Neurotherapeutics 2011; 8:63.</a></li><li><a class="nounderline abstract_t">Verma G, Woo JH, Chawla S, et al. Whole-brain analysis of amyotrophic lateral sclerosis by using echo-planar spectroscopic imaging. Radiology 2013; 267:851.</a></li><li><a class="nounderline abstract_t">Hornberger M, Kiernan MC. Emergence of an imaging biomarker for amyotrophic lateral sclerosis: is the end point near? J Neurol Neurosurg Psychiatry 2016; 87:569.</a></li><li><a class="nounderline abstract_t">Govind V, Sharma KR, Maudsley AA, et al. Comprehensive evaluation of corticospinal tract metabolites in amyotrophic lateral sclerosis using whole-brain 1H MR spectroscopy. PLoS One 2012; 7:e35607.</a></li><li><a class="nounderline abstract_t">Stagg CJ, Knight S, Talbot K, et al. Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS. Neurology 2013; 80:610.</a></li><li><a class="nounderline abstract_t">Pierpaoli C, Basser PJ. Toward a quantitative assessment of diffusion anisotropy. Magn Reson Med 1996; 36:893.</a></li><li><a class="nounderline abstract_t">Basser PJ, Pajevic S, Pierpaoli C, et al. In vivo fiber tractography using DT-MRI data. Magn Reson Med 2000; 44:625.</a></li><li><a class="nounderline abstract_t">Iwata NK, Aoki S, Okabe S, et al. Evaluation of corticospinal tracts in ALS with diffusion tensor MRI and brainstem stimulation. Neurology 2008; 70:528.</a></li><li><a class="nounderline abstract_t">Menke RA, Abraham I, Thiel CS, et al. Fractional anisotropy in the posterior limb of the internal capsule and prognosis in amyotrophic lateral sclerosis. Arch Neurol 2012; 69:1493.</a></li><li><a class="nounderline abstract_t">Filippini N, Douaud G, Mackay CE, et al. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology 2010; 75:1645.</a></li><li><a class="nounderline abstract_t">Müller HP, Turner MR, Grosskreutz J, et al. A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2016; 87:570.</a></li><li><a class="nounderline abstract_t">Jackson CE, Amato AA, Bryan WW, et al. Primary hyperparathyroidism and ALS: is there a relation? Neurology 1998; 50:1795.</a></li><li><a class="nounderline abstract_t">Rowland LP. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1998; 160 Suppl 1:S6.</a></li><li><a class="nounderline abstract_t">Reijn TS, Abdo WF, Schelhaas HJ, Verbeek MM. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol 2009; 256:615.</a></li><li><a class="nounderline abstract_t">Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2016; 87:12.</a></li><li><a class="nounderline abstract_t">Misawa S, Noto Y, Shibuya K, et al. Ultrasonographic detection of fasciculations markedly increases diagnostic sensitivity of ALS. Neurology 2011; 77:1532.</a></li><li><a class="nounderline abstract_t">Cartwright MS, Walker FO, Griffin LP, Caress JB. Peripheral nerve and muscle ultrasound in amyotrophic lateral sclerosis. Muscle Nerve 2011; 44:346.</a></li><li><a class="nounderline abstract_t">Swash M, Carvalho Md. Muscle ultrasound detects fasciculations and facilitates diagnosis in ALS. Neurology 2011; 77:1508.</a></li><li><a class="nounderline abstract_t">REED DM, KURLAND LT. MUSCLE FASCICULATIONS IN A HEALTHY POPULATION. Arch Neurol 1963; 9:363.</a></li><li><a class="nounderline abstract_t">Mitsikostas DD, Karandreas N, Coutsopetras P, et al. Fasciculation potentials in healthy people. Muscle Nerve 1998; 21:533.</a></li><li><a class="nounderline abstract_t">de Carvalho M, Swash M. Fasciculation potentials: a study of amyotrophic lateral sclerosis and other neurogenic disorders. Muscle Nerve 1998; 21:336.</a></li><li><a class="nounderline abstract_t">Blexrud MD, Windebank AJ, Daube JR. Long-term follow-up of 121 patients with benign fasciculations. Ann Neurol 1993; 34:622.</a></li><li><a class="nounderline abstract_t">Sunnerhagen KS, Grimby G. Muscular effects in late polio. Acta Physiol Scand 2001; 171:335.</a></li><li><a class="nounderline abstract_t">Chasens ER, Umlauf MG. Post-polio syndrome. Am J Nurs 2000; 100:60.</a></li><li><a class="nounderline abstract_t">Rowland LP. Progressive muscular atrophy and other lower motor neuron syndromes of adults. Muscle Nerve 2010; 41:161.</a></li><li><a class="nounderline abstract_t">HIRAYAMA K, TSUBAKI T, TOYOKURA Y, OKINAKA S. Juvenile muscular atrophy of unilateral upper extremity. Neurology 1963; 13:373.</a></li><li><a class="nounderline abstract_t">Hirayama K. [Juvenile non-progressive muscular atrophy localized in the hand and forearm--observations in 38 cases]. Rinsho Shinkeigaku 1972; 12:313.</a></li><li><a class="nounderline abstract_t">Pradhan S. Bilaterally symmetric form of Hirayama disease. Neurology 2009; 72:2083.</a></li><li><a class="nounderline abstract_t">Hosokawa T, Fujieda M, Wakiguchi H, Oosaki Y. Pediatric Hirayama disease. Pediatr Neurol 2010; 43:151.</a></li><li><a class="nounderline abstract_t">Hirayama K, Tomonaga M, Kitano K, et al. Focal cervical poliopathy causing juvenile muscular atrophy of distal upper extremity: a pathological study. J Neurol Neurosurg Psychiatry 1987; 50:285.</a></li><li><a class="nounderline abstract_t">Lehman VT, Luetmer PH, Sorenson EJ, et al. Cervical spine MR imaging findings of patients with Hirayama disease in North America: a multisite study. AJNR Am J Neuroradiol 2013; 34:451.</a></li><li><a class="nounderline abstract_t">Tsukita K, Sakamaki-Tsukita H. Hirayama disease: oblique amyotrophy and characteristic magnetic resonance imaging findings. QJM 2018; 111:583.</a></li><li><a class="nounderline abstract_t">Boruah DK, Prakash A, Gogoi BB, et al. The Importance of Flexion MRI in Hirayama Disease with Special Reference to Laminodural Space Measurements. AJNR Am J Neuroradiol 2018; 39:974.</a></li><li><a class="nounderline abstract_t">Hirayama K, Tokumaru Y. Cervical dural sac and spinal cord in juvenile muscular atrophy of distal upper extremity. Neurology 2000; 54:1922.</a></li><li><a class="nounderline abstract_t">Chen K, Yang Y, Zhu D, et al. Association of joint hypermobility with range of cervical motion and its impact on the motor unit loss in patients with Hirayama disease. Muscle Nerve 2023; 68:729.</a></li><li><a class="nounderline abstract_t">O'Sullivan DJ, McLeod JG. Distal chronic spinal muscular atrophy involving the hands. Clin Exp Neurol 1977; 14:256.</a></li><li><a class="nounderline abstract_t">Di Muzio A, Delli Pizzi C, Lugaresi A, et al. Benign monomelic amyotrophy of lower limb: a rare entity with a characteristic muscular CT. J Neurol Sci 1994; 126:153.</a></li><li><a class="nounderline abstract_t">Gourie-Devi M, Nalini A. Long-term follow-up of 44 patients with brachial monomelic amyotrophy. Acta Neurol Scand 2003; 107:215.</a></li><li><a class="nounderline abstract_t">Verma A, Bradley WG. Atypical motor neuron disease and related motor syndromes. Semin Neurol 2001; 21:177.</a></li><li><a class="nounderline abstract_t">Sobue I, Saito N, Iida M, Ando K. Juvenile type of distal and segmental muscular atrophy of upper extremities. Ann Neurol 1978; 3:429.</a></li><li><a class="nounderline abstract_t">Tandan R, Sharma KR, Bradley WG, et al. Chronic segmental spinal muscular atrophy of upper extremities in identical twins. Neurology 1990; 40:236.</a></li><li><a class="nounderline abstract_t">Nalini A, Lokesh L, Ratnavalli E. Familial monomelic amyotrophy: a case report from India. J Neurol Sci 2004; 220:95.</a></li><li><a class="nounderline abstract_t">Finsterer J. Perspectives of Kennedy's disease. J Neurol Sci 2010; 298:1.</a></li><li><a class="nounderline abstract_t">La Spada AR, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352:77.</a></li><li><a class="nounderline abstract_t">Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011; 377:942.</a></li></ol></div><div id="topicVersionRevision">Topic 5138 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15178949" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Characterization of amyotrophic lateral sclerosis and frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12833364" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cognitive impairment, frontotemporal dementia, and the motor neuron diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12682312" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Are amyotrophic lateral sclerosis patients cognitively normal?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12370467" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The overlap of amyotrophic lateral sclerosis and frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12370467" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The overlap of amyotrophic lateral sclerosis and frontotemporal dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14413775" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The plantar reflex in man, with special reference to some conditions where the extensor response is unexpectedly absent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36116464" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7807156" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11464847" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7595600" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The validation of El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis: a clinicopathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20536375" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sensitivity and specificity of the 'Awaji' electrodiagnostic criteria for amyotrophic lateral sclerosis: retrospective comparison of the Awaji and revised El Escorial criteria for ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11771769" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Are the El Escorial and Revised El Escorial criteria for ALS reproducible? A study of inter-observer agreement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30573424" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diagnostic criteria for amyotrophic lateral sclerosis: A multicentre study of inter-rater variation and sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10927797" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32029539" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Primary lateral sclerosis: consensus diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32387049" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A proposal for new diagnostic criteria for ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33565111" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Diagnostic Utility of Gold Coast Criteria in Amyotrophic Lateral Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33565111" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diagnostic Utility of Gold Coast Criteria in Amyotrophic Lateral Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11003783" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12795519" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Amyotrophic lateral sclerosis and other motor neuron diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22892641" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Awaji criteria for the diagnosis of amyotrophic lateral sclerosis:a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10679710" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nerve conduction studies in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11464940" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Motor unit number estimation (MUNE): how may it contribute to the diagnosis of ALS?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11908235" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Motor unit number estimation in neurologic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15512887" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : ALS surrogate markers. MUNE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15911812" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Quantitating progression in ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13465824" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Electromyographic studies in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14425103" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Myasthenic syndrome in patients with amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15534253" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Decrement in surface-recorded motor unit potentials in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15452842" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Single motor unit variability with threshold stimulation in patients with amyotrophic lateral sclerosis and normal subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11552026" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prognostic value of decremental responses to repetitive nerve stimulation in ALS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8008001" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Decremental motor responses to repetitive nerve stimulation in ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/218540" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Amyotrophic lateral sclerosis. Impairment of neuromuscular transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4360143" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Amyotrophic lateral sclerosis. Electrophysiologic study (number of motor units and rate of decay of motor units).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/216781" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Changes in motor unit populations in motor neurone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15603713" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Single fiber electromyography in 78 patients with amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21382747" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cortical excitability distinguishes ALS from mimic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18164242" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Electrodiagnostic criteria for diagnosis of ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11574102" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Proton magnetic resonance spectroscopy and transcranial magnetic stimulation for the detection of upper motor neuron degeneration in ALS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10540036" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Transcranial magnetic stimulation compared with upper motor neuron signs in patients with amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11898584" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Amyotrophic lateral sclerosis: objective upper motor neuron markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15159473" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11464941" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Transcranial magnetic stimulation (TMS): compared sensitivity of different motor response parameters in ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10400213" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Motor neuron disease: usefulness of transcranial magnetic stimulation in improving the diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19204259" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Transcranial magnetic stimulation in ALS: utility of central motor conduction tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25843898" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30709964" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Amyotrophic lateral sclerosis diagnostic index: Toward a personalized diagnosis of ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30635480" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Upper motor neuron assessment and early diagnosis in ALS: Getting it right the first time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10478245" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Motor neuron diseases: comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8234713" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35593959" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Iron-sensitive MR imaging of the primary motor cortex to differentiate hereditary spastic paraplegia from other motor neuron diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31521959" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The motor band sign in ALS: presentations and frequencies in a consecutive series of ALS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24888543" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Usefulness of SWI for the Detection of Iron in the Motor Cortex in Amyotrophic Lateral Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21511189" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Towards a neuroimaging biomarker for amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21274686" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Neuroimaging in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23360740" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Whole-brain analysis of amyotrophic lateral sclerosis by using echo-planar spectroscopic imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26929028" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Emergence of an imaging biomarker for amyotrophic lateral sclerosis: is the end point near?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22539984" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comprehensive evaluation of corticospinal tract metabolites in amyotrophic lateral sclerosis using whole-brain 1H MR spectroscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23325907" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8946355" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Toward a quantitative assessment of diffusion anisotropy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11025519" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : In vivo fiber tractography using DT-MRI data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18268244" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Evaluation of corticospinal tracts in ALS with diffusion tensor MRI and brainstem stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22910997" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Fractional anisotropy in the posterior limb of the internal capsule and prognosis in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21041787" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26746186" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9633730" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Primary hyperparathyroidism and ALS: is there a relation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9851643" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Diagnosis of amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19296046" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : CSF neurofilament protein analysis in the differential diagnosis of ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26296871" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21940619" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Ultrasonographic detection of fasciculations markedly increases diagnostic sensitivity of ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21815172" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Peripheral nerve and muscle ultrasound in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21940612" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Muscle ultrasound detects fasciculations and facilitates diagnosis in ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14060084" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : MUSCLE FASCICULATIONS IN A HEALTHY POPULATION.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9533790" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Fasciculation potentials in healthy people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486862" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Fasciculation potentials: a study of amyotrophic lateral sclerosis and other neurogenic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8215252" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Long-term follow-up of 121 patients with benign fasciculations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11412146" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Muscular effects in late polio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11202787" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Post-polio syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20082312" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Progressive muscular atrophy and other lower motor neuron syndromes of adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13954749" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Juvenile muscular atrophy of unilateral upper extremity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4674765" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : [Juvenile non-progressive muscular atrophy localized in the hand and forearm--observations in 38 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19528514" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Bilaterally symmetric form of Hirayama disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610130" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Pediatric Hirayama disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3559609" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Focal cervical poliopathy causing juvenile muscular atrophy of distal upper extremity: a pathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22878010" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Cervical spine MR imaging findings of patients with Hirayama disease in North America: a multisite study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29518243" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Hirayama disease: oblique amyotrophy and characteristic magnetic resonance imaging findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29545250" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The Importance of Flexion MRI in Hirayama Disease with Special Reference to Laminodural Space Measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10822430" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cervical dural sac and spinal cord in juvenile muscular atrophy of distal upper extremity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37638794" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Association of joint hypermobility with range of cervical motion and its impact on the motor unit loss in patients with Hirayama disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/616604" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Distal chronic spinal muscular atrophy involving the hands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7853021" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Benign monomelic amyotrophy of lower limb: a rare entity with a characteristic muscular CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614316" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Long-term follow-up of 44 patients with brachial monomelic amyotrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11442326" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Atypical motor neuron disease and related motor syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/727722" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Juvenile type of distal and segmental muscular atrophy of upper extremities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2300241" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Chronic segmental spinal muscular atrophy of upper extremities in identical twins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15140613" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Familial monomelic amyotrophy: a case report from India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846673" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Perspectives of Kennedy's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2062380" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21296405" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Amyotrophic lateral sclerosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
